• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Medpace Holdings Inc.

    5/19/26 2:43:27 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MEDP alert in real time by email
    8-K
    false 0001668397 --12-31 0001668397 2026-05-15 2026-05-15
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): May 15, 2026

     

     

    MEDPACE HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Delaware   001-37856   32-0434904

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    5375 Medpace Way

    Cincinnati, Ohio 45227

    (Address of Principal Executive Offices, and Zip Code)

    (513) 579-9911

    Registrant’s Telephone Number, Including Area Code

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock $0.01 par value   MEDP   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.03.

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    At the Medpace Holdings, Inc. (the “Company”) 2026 Annual Meeting of Stockholders held on May 15, 2026 (the “2026 Annual Meeting”), stockholders approved separate amendments (the “Amendments”) to the Restated Certificate of Incorporation of the Company, each as described in the Company’s proxy materials related to the 2026 Annual Meeting, (i) to remove supermajority voting requirements and (ii) to remove the limitation on stockholders calling special meetings of stockholders. The Amendments became effective immediately upon the filing of a certificate of amendment setting forth the same with the Secretary of State of the State of Delaware on May 18, 2026. Following the filing of this certificate of amendment, the Company filed a Restated Certificate of Incorporation of the Company integrating the same with the Secretary of State of the State of Delaware on May 18, 2026, which became effective upon filing.

    In connection with the Amendments, the Board approved amendments to the Second Amended and Restated Bylaws of the Company to remove the limitation on stockholders calling special meetings of stockholders, to provide one or more stockholders as a group owning at least 25% of the voting power of the Company’s outstanding shares the right to call a special meeting, and to implement other conforming and clarifying changes (the “Bylaw Amendments”). The right of stockholders to request that the Company call special meetings is also subject to notice, information, and other requirements and limitations set forth in the Third Amended and Restated Bylaws of the Company, including a requirement that the requesting stockholders must have continuously owned at least 25% of the voting power of our outstanding shares for one year.

    The foregoing summaries of the Amendments and the Bylaw Amendments are qualified in their entirety by reference to the full text of the Restated Certificate of Incorporation and the Third Amended and Restated Bylaws, as set forth in Exhibits 3.1 and 3.2 to this Current Report on Form 8-K, respectively, and incorporated herein by reference.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

     

      (a)

    On May 15, 2026, the Company held its 2026 Annual Meeting.

     

      (b)

    Stockholders voted on the matters set forth below.

    Proposal 1 — Election of Directors

    The following nominees were elected to the Company’s Board of Directors to serve as Directors until the Company’s 2027 Annual Meeting of Stockholders based upon the following votes:

     

         Votes
    For
         Votes
    Withheld
         Broker
    Non-Votes
     

    Brian T. Carley (Class I)

         22,251,529        2,170,699        1,545,538  

    Femida H. Gwadry-Sridhar (Class I)

         23,736,619        685,609        1,545,538  

    Robert O. Kraft (Class I)

         22,148,880        2,273,348        1,545,538  

    August J. Troendle (Class III)

         23,900,589        521,639        1,545,538  

    Dani S. Zander (Class III)

         23,721,072        701,156        1,545,538  

     


    Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm

    The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based upon the following votes:

     

    Votes
    For

      

    Votes
    Against

      

    Votes
    Abstained

      

    Broker
    Non-Votes

    25,269,569    675,125    23,072    — 

    Proposal 3 — Advisory Vote on the Compensation of Our Named Executive Officers

    The proposal to approve, on an advisory basis, the compensation of the Company’s Named Executive Officers was approved based upon the following votes:

     

    Votes
    For

     

    Votes
    Against

     

    Votes
    Abstained

     

    Broker
    Non-Votes

    22,656,335   1,737,558   28,335   1,545,538

    Proposal 4 — Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of Our Named Executive Officers

    The proposal to approve, on an advisory basis, the frequency of future advisory votes on the compensation of the Company’s Named Executive Officers received the following votes:

     

    Votes For

    One Year

     

    Votes For

    Two Years

     

    Votes For

    Three Years

     

    Votes Abstained

    23,989,262   12,741   402,376   17,849

    Proposal 5 — Amendment to the Company’s Certificate of Incorporation to Remove Supermajority Voting Requirements.

    The proposal to amend the Company’s Certificate of Incorporation to remove supermajority voting requirements was approved based upon the following votes:

     

    Votes

    For

     

    Votes

    Against

     

    Votes

    Abstained

     

    Broker

    Non-Votes

    24,311,938   95,085   15,205   1,545,538

    Proposal 6 — Amendment to the Company’s Certificate of Incorporation to Remove the Limitation on Stockholders Calling Special Meetings of Stockholders.

    The proposal to amend the Company’s Certificate of Incorporation to remove the limitation on stockholders calling special meetings of stockholders was approved based upon the following votes:

     

    Votes

    For

     

    Votes

    Against

     

    Votes

    Abstained

     

    Broker

    Non-Votes

    22,596,141   322,485   1,503,602   1,545,538

     


    Proposal 7 — Advisory Vote on Stockholder Proposal

    The non-binding advisory stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting received the following votes:

     

    Votes

    For

     

    Votes

    Against

     

    Votes

    Abstained

     

    Broker

    Non-Votes

    8,306,071

      16,081,493   34,664   1,545,538

    (c) Not applicable.

    (d) Based upon the results set forth in item (b) (Proposal 4) above, and consistent with the Board’s recommendation, the Board of Directors has determined that advisory votes on executive compensation will be submitted to stockholders on an annual basis until the next required vote on the frequency of such votes.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    No.

      

    Description

    3.1    Restated Certificate of Incorporation
    3.2    Third Amended and Restated Bylaws
    104    Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        MEDPACE HOLDINGS, INC.
    Date: May 19, 2026     By:  

    /s/ Stephen P. Ewald

        Name:   Stephen P. Ewald
        Title:   General Counsel and Corporate Secretary
    Get the next $MEDP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MEDP

    DatePrice TargetRatingAnalyst
    3/6/2026$500.00Underweight → Equal Weight
    Barclays
    3/3/2026$522.00Outperform
    RBC Capital Mkts
    2/18/2026$419.00Sell → Hold
    TD Cowen
    2/13/2026$560.00Hold → Buy
    Jefferies
    2/10/2026$564.00Neutral → Outperform
    Robert W. Baird
    11/13/2025$600.00Market Perform
    BMO Capital Markets
    10/2/2025$425.00Equal Weight → Underweight
    Barclays
    9/3/2025$474.00Buy → Neutral
    Rothschild & Co Redburn
    More analyst ratings

    $MEDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    6/1/26 4:27:45 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Zander Dani S.

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    5/18/26 5:30:14 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Mccarthy Cornelius P. Iii

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    5/18/26 5:23:38 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medpace Holdings, Inc. Reports First Quarter 2026 Results

    Revenue of $706.6 million in the first quarter of 2026 increased 26.5% from revenue of $558.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.3%. Net new business awards were $618.4 million in the first quarter of 2026, representing an increase of 23.7% from net new business awards of $500.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.88x. First quarter of 2026 GAAP net income was $123.9 million, or $4.28 per diluted share, versus GAAP net income of $114.6 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 17.5% and 20.5% for the first quarter of

    4/22/26 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

    Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be

    3/24/26 4:05:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

    Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1% from net new business awards of $529.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Fourth quarter of 2025 GAAP net income was $135.1 million, or $4.67 per diluted share, versus GAAP net income of $117.0 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 19.1% and 21.8% for the fourth quarter

    2/9/26 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medpace upgraded by Barclays with a new price target

    Barclays upgraded Medpace from Underweight to Equal Weight and set a new price target of $500.00

    3/6/26 8:19:59 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    RBC Capital Mkts initiated coverage on Medpace with a new price target

    RBC Capital Mkts initiated coverage of Medpace with a rating of Outperform and set a new price target of $522.00

    3/3/26 8:27:50 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace upgraded by TD Cowen with a new price target

    TD Cowen upgraded Medpace from Sell to Hold and set a new price target of $419.00

    2/18/26 7:50:53 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    SEC Filings

    View All

    $MEDP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 8-K filed by Medpace Holdings Inc.

    8-K - Medpace Holdings, Inc. (0001668397) (Filer)

    5/19/26 2:43:27 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Medpace Holdings Inc.

    10-Q - Medpace Holdings, Inc. (0001668397) (Filer)

    4/23/26 4:03:37 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Medpace Holdings, Inc. (0001668397) (Filer)

    4/22/26 4:15:52 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    General Counsel & Corp. Secy. Ewald Stephen P bought $652 worth of shares (2 units at $326.11), increasing direct ownership by 0.01% to 13,343 units (SEC Form 4)

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    2/28/25 4:39:05 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Financials

    Live finance-specific insights

    View All

    Medpace Holdings, Inc. Reports First Quarter 2026 Results

    Revenue of $706.6 million in the first quarter of 2026 increased 26.5% from revenue of $558.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.3%. Net new business awards were $618.4 million in the first quarter of 2026, representing an increase of 23.7% from net new business awards of $500.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.88x. First quarter of 2026 GAAP net income was $123.9 million, or $4.28 per diluted share, versus GAAP net income of $114.6 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 17.5% and 20.5% for the first quarter of

    4/22/26 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

    Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be

    3/24/26 4:05:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

    Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1% from net new business awards of $529.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Fourth quarter of 2025 GAAP net income was $135.1 million, or $4.67 per diluted share, versus GAAP net income of $117.0 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 19.1% and 21.8% for the fourth quarter

    2/9/26 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Leadership Updates

    Live Leadership Updates

    View All

    Medpace Holdings, Inc. Announces Senior Leadership Changes

    Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon

    7/26/21 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

    SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

    3/8/24 4:28:58 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

    SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

    2/28/24 5:04:01 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by Medpace Holdings Inc. (Amendment)

    SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)

    2/13/24 5:09:38 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care